Department of Cancer Biology, Lerner Research Institute, Cleveland Clinicgrid.239578.2 Foundation, Cleveland, Ohio, USA.
Department of Microbiology, Perlman School of Medicine at the University of Pennsylvaniagrid.25879.31, Philadelphia, Pennsylvania, USA.
mBio. 2021 Aug 31;12(4):e0178121. doi: 10.1128/mBio.01781-21. Epub 2021 Aug 10.
The 2',5'-oligoadenylate (2-5A)-dependent endoribonuclease, RNase L, is a principal mediator of the interferon (IFN) antiviral response. Therefore, the regulation of cellular levels of 2-5A is a key point of control in antiviral innate immunity. Cellular 2-5A levels are determined by IFN-inducible 2',5'-oligoadenylate synthetases (OASs) and by enzymes that degrade 2-5A. Importantly, many coronaviruses (CoVs) and rotaviruses encode 2-5A-degrading enzymes, thereby antagonizing RNase L and its antiviral effects. A-kinase-anchoring protein 7 (AKAP7), a mammalian counterpart, could possibly limit tissue damage from excessive or prolonged RNase L activation during viral infections or from self-double-stranded RNAs that activate OAS. We show that these enzymes, members of the two-histidine phosphoesterase (2H-PE) superfamily, constitute a subfamily referred here as 2',5'-PEs. 2',5'-PEs from the mouse CoV mouse hepatitis virus (MHV) (NS2), Middle East respiratory syndrome coronavirus (MERS-CoV) (NS4b), group A rotavirus (VP3), and mouse (AKAP7) were investigated for their evolutionary relationships and activities. While there was no activity against 3',5'-oligoribonucleotides, they all cleaved 2',5'-oligoadenylates efficiently but with variable activity against other 2',5'-oligonucleotides. The 2',5'-PEs are shown to be metal ion-independent enzymes that cleave trimer 2-5A (2',5'-pA) producing mono- or diadenylates with 2',3'-cyclic phosphate termini. Our results suggest that the elimination of 2-5A might be the sole function of viral 2',5'-PEs, thereby promoting viral escape from innate immunity by preventing or limiting the activation of RNase L. Viruses often encode accessory proteins that antagonize the host antiviral immune response. Here, we probed the evolutionary relationships and biochemical activities of two-histidine phosphoesterases (2H-PEs) that allow some coronaviruses and rotaviruses to counteract antiviral innate immunity. In addition, we investigated the mammalian enzyme AKAP7, which has homology and shared activities with the viral enzymes and might reduce self-injury. These viral and host enzymes, which we refer to as 2',5'-PEs, specifically degrade 2',5'-oligoadenylate activators of the antiviral enzyme RNase L. We show that the host and viral enzymes are metal ion independent and exclusively cleave 2',5'- and not 3',5'-phosphodiester bonds, producing cleavage products with cyclic 2',3'-phosphate termini. Our study defines 2',5'-PEs as enzymes that share characteristic conserved features with the 2H-PE superfamily but have specific and distinct biochemical cleavage activities. These findings may eventually lead to pharmacological strategies for developing antiviral drugs against coronaviruses, rotaviruses, and other viruses.
2',5'-寡聚腺苷酸(2-5A)依赖性内切核糖核酸酶,RNase L,是干扰素(IFN)抗病毒反应的主要介质。因此,细胞内 2-5A 的调节是抗病毒先天免疫的一个关键点。细胞内 2-5A 的水平由 IFN 诱导的 2',5'-寡聚腺苷酸合成酶(OASs)和降解 2-5A 的酶决定。重要的是,许多冠状病毒(CoVs)和轮状病毒编码 2-5A 降解酶,从而拮抗 RNase L 及其抗病毒作用。锚定蛋白激酶 A 激酶 7(AKAP7)是哺乳动物的对应物,可能会限制组织损伤,防止病毒感染过程中 RNase L 过度或持续激活,或防止自身双链 RNA 激活 OAS。我们表明,这些酶,属于双组氨酸磷酸酯酶(2H-PE)超家族的成员,构成了一个亚家族,这里称为 2',5'-PEs。我们研究了来自鼠冠状病毒鼠肝炎病毒(MHV)(NS2)、中东呼吸综合征冠状病毒(MERS-CoV)(NS4b)、A 组轮状病毒(VP3)和小鼠(AKAP7)的 2',5'-PEs 的进化关系和活性。虽然对 3',5'-寡核苷酸没有活性,但它们都能有效地切割 2',5'-寡腺苷酸,但对其他 2',5'-寡核苷酸的活性不同。结果表明,2',5'-PEs 是金属离子非依赖性酶,可切割三核苷酸 2-5A(2',5'-pA),产生具有 2',3'-环磷酸酯末端的单或二腺苷酸。我们的结果表明,2-5A 的消除可能是病毒 2',5'-PEs 的唯一功能,从而通过阻止或限制 RNase L 的激活来促进病毒逃避先天免疫。病毒通常编码辅助蛋白,拮抗宿主抗病毒免疫反应。在这里,我们探测了双组氨酸磷酸酯酶(2H-PE)的进化关系和生化活性,这些酶允许一些冠状病毒和轮状病毒对抗抗病毒先天免疫。此外,我们还研究了具有同源性和共享活性的哺乳动物酶 AKAP7,它可能减轻自身损伤。我们将这些病毒和宿主酶称为 2',5'-PEs,它们专门降解 2',5'-寡腺苷酸激活抗病毒酶 RNase L。我们表明,宿主和病毒酶是金属离子非依赖性的,并且仅切割 2',5'-而不是 3',5'-磷酸二酯键,产生具有 2',3'-环磷酸酯末端的切割产物。我们的研究将 2',5'-PEs 定义为具有与 2H-PE 超家族特征性保守特征的酶,但具有特定和不同的生化切割活性。这些发现最终可能导致开发针对冠状病毒、轮状病毒和其他病毒的抗病毒药物的药理学策略。
Proc Natl Acad Sci U S A. 2013-7-22
Proc Natl Acad Sci U S A. 2024-1-30
Crit Rev Biochem Mol Biol. 2022
Proc Natl Acad Sci U S A. 2021-4-20
Nat Rev Mol Cell Biol. 2020-5-18
J Exp Med. 2020-5-4
Cell. 2019-11-27
Proc Natl Acad Sci U S A. 2019-2-27
Sci Rep. 2018-11-2